Joint Filing AgreementJoint Filing Agreement • September 4th, 2018 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated September 4, 2018 with respect to the common stock, par value $0.001 per share of Five Prime Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
